FMP
May 25, 2023 5:00 PM - Davit Kirakosyan(Last modified: Dec 19, 2023 5:49 PM)
Image credit: FMP
OptimizeRx Corporation (NASDAQ:OPRX) reaffirmed its 2023 over 10% revenue growth outlook, provided a positive update concerning the visibility it now has into achieving that target, and also introduced longer-term goals of reaching $100-120 million revenue and 20% EBITDA margin within the next 18-24 months.
Underpinning its confidence in the latter, management cites strong macro tailwinds, expanded offerings and strengthening commercial momentum.
Analysts at RBC Capital find all these encouraging but also noted growth thus far has been choppy, and absent M&A, achieving even the low end of the long-term revenue target would require a meaningful multi-year acceleration from 2022 and 2023 levels.
Aug 7, 2024 3:53 AM - Parth Sanghvi
Interest rates play a crucial role in the economy and financial markets, influencing everything from consumer behavior to investment decisions. Understanding their impact is essential for making informed financial and investment decisions. This comprehensive analysis delves into how interest rates a...
Sep 10, 2024 7:33 AM - Parth Sanghvi
When it comes to downloading historical stock data, Yahoo Finance has been a popular choice for many. However, for those looking for more comprehensive, accurate, and flexible options, Financial Modeling Prep (FMP) offers a suite of powerful tools and services that stand out as superior alternatives...
Nov 8, 2024 5:30 AM - Sanzhi Kobzhan
When it comes to investing in stocks, one of the key decisions an investor must make involves determining the intrinsic value of a company's shares. Equity valuation isn't just about numbers, it's an art mixed with science, aiming to predict future performance based on current and historical data. H...